HPLC-UV METHOD APPROACH FOR THE ANALYSIS AND IMPURITY PROFILING OF CAPTOPRIL
DOI:
https://doi.org/10.24193/subbchem.2019.2.19Keywords:
captopril, impurities, stability indicating method, degradationAbstract
The aim of the study was to propose an improved HPLC/UV method for captopril impurity profiling based on forced degradation studies. Material and methods: the HPLC-UV analyses were performed on a Luna C18 column at 50 0C by using a mobile phase consisting of phosphoric acid 15 mM and acetonitrile at 210 nm. Results and discussions: an HPLC method with superior characteristics to one described in the European Pharmacopoeia for captopril impurities profiling was proposed. The main degradation product of captopril was captopril disulfide (Impurity A), the concentration of which increases in all the conditions of forced degradation, except thermal degradation. UV light has led to the highest number of unknown impurities, but the oxidative degradation presented the highest rate of degradation (>88%). A total of 15 unknown impurities have been observed with significant area (>0.50%), who were not initially present in the captopril sample. Conclusions: The proposed HPLC method can be successfully applied in pharmaceutical analysis laboratories as a stability indicating method of captopril, allowing the separation of official impurities A, B, C, D and E and those formed under forced degradation conditions.
References
I. Kancirová, M. Jašová, I. Waczulíková, T. Ravingerová, A. Ziegelhöffer, M. Ferko, Iranian Journal of Basic Medical Science, 2016,19(6), 615-623.
J. Leanpolchareanchai, J. Suksiriworapong, Journal of Pharmaceutical Sciences, 2015, 42(2), 85-92.
W.M. Mahmoud, K. Kümmerer, Chemosphere, 2012, 88, 1170–1177.
R. Nogueira, W. Wollinger, T.E. Da Silva et al, Brazilian Journal of Pharmaceutical Sciences, 2011, 47(2), 351-362.
S. Imre, S. Vancea, D.L. Muntean, E. Sipos, A. Cociş, V. Avrigeanu, E. Mircia, Revista Medico-Chirurgicală a Societăţii de Medici şi Naturalişti din Iaşi, 2008, 112(3), 848-855.
N. Rastkari, M. Khoob, A. Shafiee, M.R. Khoshayand, R. Ahmadkhaniha, Journal of Chromatography B, 2013, 932, 144–151.
J.R. Lino e Freitas, F.J Oliveira Quintao, J.C Cardoso da Silva et al, International Journal of Environmental Analytical Chemistry, 2017, 1, 42-55.
T. Rawat, I.P. Pandey, Journal of Pharmaceutical Sciences and Research, 2015, 7(5), 238-241.
M. Blessy, R.D. Patel, P.N. Prajapati, Y.K. Agrawal, Journal of Pharmaceutical Analysis, 2014, 4(3), 159–165.
M.R. Pabari, C. McDermott, J. Barlow, Z. Ramtoola, Clinical Therapeutics, 2012, 34, 2221-2229.
***European Pharmacopoeia 9ᵗʰ edition, 2017.
ICH Expert Working Group – Stability testing of new drug substances and products, ICH Harmonised Tripartite Guideline, 2003.
A. Gindy, M.W. Nassar, K.A. Salam Attia, H.H. Abu-Seada, M. El-Ghandour, Journal of Liquid Chromatography & Related Technologies, 2014, 37, 696–712.
S. Valizadeh, M. Rasekhi, H. Hamishehkar, M. Asadollahi, H. Hamishehka, Journal of Research Pharmacy Practice, 2015, 4(3),147–152.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 Studia Universitatis Babeș-Bolyai Chemia
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.